FindTrial
Sign In

BBO-10203

DRUG3 trials

Sponsors

TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)

Conditions

Advanced Breast CancerAdvanced Lung CancerAdvanced Lung CarcinomaCRC (Colorectal Cancer)HER2 Mutation-Related TumorsHER2-positive Advanced Breast CancerHER2-positive Metastatic Breast CancerHR-positive, HER2-negative Advanced Breast Cancer

Phase 1

Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
RecruitingNCT06343402
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)Advanced Lung Carcinoma, KRAS G12C, Metastatic Lung Cancer +3
Start: 2024-05-22End: 2031-09-01Target: 350Updated: 2026-09-03
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
RecruitingNCT06625775
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)Advanced Breast Cancer, Advanced Lung Cancer, HER2 Mutation-Related Tumors +8
Start: 2024-10-29End: 2028-11-01Target: 392Updated: 2026-09-09
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
RecruitingNCT06917079
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)Advanced Lung Carcinoma, CRC (Colorectal Cancer), KRAS G12A +11
Start: 2025-03-31End: 2029-09-01Target: 665Updated: 2026-06-02

Related Papers

Abstract 6780: The RAS: PI3Kα breaker BBO-10203 inhibits PI3Kα/AKT activity in HER2+ models through non-canonical RAS signaling blockade
Cancer Research2026-04-03
Abstract 7104: BBO-11818: An orally bioavailable, highly potent and selective non-covalent pan-KRAS(ON) and (OFF) inhibitor with robust anti-tumor activity in KRAS-mutant preclinical models
Cancer Research2026-04-03
Data from Discovery of BBO-11818, a Potent and Selective Noncovalent Inhibitor of (ON) and (OFF) KRAS with Activity against Multiple Oncogenic Mutants
2026-04-01
Discovery of BBO-11818, a Potent and Selective Noncovalent Inhibitor of (ON) and (OFF) KRAS with Activity against Multiple Oncogenic Mutants.
2026-03-06
Abstract PS5-07-06: BREAKER-101: a phase 1a/1b open-label study evaluating the safety, tolerability, pharmacokinetics, and efficacy of BBO-10203 in patients with advanced solid tumors
Clinical Cancer Research2026-02-17
Abstract PS2-12-06: BBO-10203, a first-in-class breaker of the RAS:PI3Kα interaction, inhibits tumor growth alone and in combination with fulvestrant or ribociclib in breast cancer models without inducing hyperglycemia
Clinical Cancer Research2026-02-17
Abstract C082: BBO-10203, a first-in-class, orally bioavailable, selective breaker of the RAS:PI3Kα interaction inhibits tumor growth alone and in combination with KRAS inhibitors in KRAS mutant models without inducing hyperglycemia
Molecular Cancer Therapeutics2025-10-22
Abstract A063: BBO-11818: an orally bioavailable, highly potent and selective non-covalent pan-KRAS(ON) and (OFF) inhibitor with robust anti-tumor activity in KRAS-mutant preclinical models
Molecular Cancer Therapeutics2025-10-22
Onkoras-101: A phase 1a/1b open-label study evaluating the safety, tolerability, pharmacokinetics, and efficacy of BBO-8520 in subjects with advanced KRAS <sup>G12C</sup> mutant non-small-cell lung cancer.
Journal of Clinical Oncology2025-05-28
Abstract 3788: BBO-8520, a first-in-class direct dual inhibitor of GTP-bound (ON) and GDP-bound (OFF) KRASG12C, exhibits robust efficacy in non-small cell lung cancer preclinical models
Cancer Research2025-04-21